Trial site
European Interbalkan Medical Center
Thessaloniki, 57001, GreeceNot linked to an institution yet
- 14running trials
- 2closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 12 trials
- Phase 1/21 trial
- Phase 21 trial
- Status
- Recruiting6 trials
- Active, not recruiting5 trials
- Not yet recruiting3 trials
- Completed1 trial
- Terminated1 trial
- Lead sponsor
- Amgen6 trials
- Eli Lilly and Company4 trials
- BioAtla, Inc.1 trial
- Cardiac Dimensions, Inc.1 trial
- Javelin Medical1 trial
- and 3 more
Running trials
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644· Phase 3· SystImmune Inc.· Source
Contact: Ippokratis Korantzis (principal investigator)
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Contact: Ippokratis Korantzis (principal investigator)
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674· Phase 3· Amgen· Source
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593· Phase 3· Eli Lilly and Company· Source
Contact: Georgios Giannakoulas (principal investigator)
Active, not recruiting
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· Phase 3· Amgen· Source
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Contact: Sofia Baka (principal investigator)
Active, not recruiting
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951· Phase 1· Amgen· Source
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· Phase 3· Amgen· Source
Active, not recruiting
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354· Phase 1· Amgen· Source
Active, not recruiting
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308· Phase 3· Eli Lilly and Company· Source
Recruiting
The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients
NCT04405583· Occlutech International AB· Source
Contact: Gönül Sonmez Utkun
Active, not recruiting
Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants
NCT03892824· Javelin Medical· Source
Recruiting
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
NCT03142152· Cardiac Dimensions, Inc.· Source
Contact: Sosanna Konstantinidou
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error